NeuroDx

Executive Summary

NeuroDx is a digital health company transforming neurological disorder diagnostics through AI-powered analysis of multimodal biomarkers, including speech, movement, and digital data. Founded in 2017 and based in New York, the company has raised $165 million and operates at the commercial stage, targeting early detection and monitoring of Alzheimer's, Parkinson's, and multiple sclerosis. By leveraging machine learning, NeuroDx aims to provide objective, scalable tools that replace subjective assessments, potentially improving patient outcomes and reducing healthcare costs. With a strong funding base and a focus on high-need neurological conditions, the company is positioned for growth in the expanding digital diagnostics market, though it faces regulatory hurdles and competition from established players. Key upcoming catalysts include product launches and regulatory clearances, which could drive adoption and revenue.

Upcoming Catalysts (preview)

• Q2 2026FDA Clearance for Alzheimer's Digital Diagnostic Tool75% success
• Q3 2026Commercial Partnership with Major Health System70% success
• Q4 2026Launch of Parkinson's Disease Monitoring Platform65% success